2019
Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
Blauvelt A, Strober B, Langley R, Kavanagh S, Arendt C, Boehnlein M, Lebwohl M, Reich K. Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal Of Cutaneous Medicine 2019, 3: s39. DOI: 10.25251/skin.3.supp.39.Peer-Reviewed Original Research
2018
Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
Blauvelt A, Strober B, Langley R, Burge D, Pisenti L, Yassine M, Kavanagh S, Arendt C, Rolleri R, Reich K. Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. SKIN The Journal Of Cutaneous Medicine 2018, 2: s16. DOI: 10.25251/skin.2.supp.16.Peer-Reviewed Original Research